Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by retiredcopon Jul 07, 2018 9:14am
154 Views
Post# 28283370

Biogen is the Company We ALL Cheer for Now

Biogen is the Company We ALL Cheer for Now 2008=2009 ANNUAL REPORT “ AmorfixLifeSciences. Ltd the company or Amorfix is an emerging theranostics company ...... appearing in publications such as Barrons the International.”

I used to follow Barrons as they did cover AMF a numer of articles a few years ago. Great article just posted that shows the significance of BIogen and how their success will be a benefit to other companies using the amyloid approach. 
_____________________________________________________________________________

Shares of Biogen took off—which could be a sign it’s safe to start nibbling on shares of other big biotech stocks

6 July 2018 
BARRONS.COM
The Biogen Bump Bodes Well for Biotech
Biogen's surge today could be a sign that it’s safe to start nibbling on the shares of other big biotech stocks as well.
 

Bullboard Posts